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Abstracts
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School of Medicine, Yokohama City University, Yokohama, Kanagawa, 
Japan, 13Department of Pathology, Hyogo Prefectural Kobe Children’s 
Hospital, Kobe, Hyogo, Japan, 14Department of Neurosurgery, Hyogo 
Prefectural Kobe Children’s Hospital, Kobe, Hyogo, Japan, 15Department 
of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, 
Japan, 16Department of Neurosurgery, Saitama Children’s Medical Center, 
Saitama, Japan, 17Department of Neurosurgery, Kyorin University Faculty 
of Medicine, Mitaka, Tokyo, Japan, 18Department of Neurosurgery, Faculty 
of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
BACKGROUND: Central nervous system germ cell tumor (CNSGCT) is 
a rare pediatric brain tumor. However, they are found at a relatively high 
incidence in East Asia. Germinoma is sensitive toward radiotherapy and 
chemotherapy; however, non-germinoma GCTs (NGGCT) often show poor 
response. Some cases are a mixture of germinoma and NGGCT (mixed 
GCT), and they sometimes change histological subtypes at recurrence. 
Previous report demonstrated that a germinoma and NGGCT component 
within the same mixed GCT tissue shared the same gene mutation, whereas 
the genome-wide methylation profiles were distinct from each other. The 
methylation profiles of germinoma was similar to the primordial germ 
cells (PGC) at the migration phase, supporting a model that PGC is the 
cell of origin for CNSGCT. However, tumor heterogeneity hinder informa-
tion of the mixed bulk RNA-sequence data, causing difficulty in elucidating 
the mechanism of tumor development. The purpose of this study was to 
investigate the tumor cells subpopulations at the resolution of individual 
cells by single-cell RNA-seq.  RESULTS: Fresh surgical tumor tissue was 
immediately dissociated mechanically and enzymatically. Tumor cells are 
separated from CD45-labelled lymphocytes by FACS, and libraries were 
generated by Chromium Single cell 3’ Reagent Kit. Total of 11 tumor sam-
ples were collected and sequenced. Unsupervised Clustering showed indi-
vidual clusters. One of the clusters had high expression of Oct-4, which is 
a marker of germinoma. The other clusters showed different subtypes of 
cells representing the heterogeneity of CNSGCT. Further analysis including 
a pseudo-time course analysis is underway to identify the lineage of tumor 
cell development.
GCT-63. STEREOTACTIC RADIOSURGERY FOR RESIDUAL LESIONS 
OF PINEAL NON-GERMINOMATOUS GERM CELL TUMORS AFTER 
CONVENTIONAL RADIOTHERAPY: A RETROSPECTIVE STUDY
Mingyao Lai, Juan Li, Qingjun Hu, Zhaoming Zhou, Lei Wen, 
Cheng Zhou, Changguo Shan, and Linbo Cai; Guangdong Sanjiu Brain 
Hospital, Guangzhou, Guangdong, China
OBJECTIVE: To explore the efficacy and safety of SRS for residual le-
sions of NGGCTs after conventional RT. METHODS: The clinical data of 
patients with iGCT who were admitted to Department of Oncology, Guang-
dong Sanjiu Brain Hospital between January 1, 2008 and December 30, 
2019 were gathered. Those who were pathologically or clinically diagnosed 
with NGGCTs, with lesions located at pineal region, limited stage and re-
sidual lesions (with a maximum diameter>10mm) of pineal NGGCTs after 
RT with a total dose of 50-54Gy/25-30f, were eligible for the study. Several 
indexes such as local control rate, PFS, OS and treatment-related toxicity 
were analyzed.  RESULTS: A total of 27 patients were included; all were 
male, with a median age of 16 years (range 8–31 years). The patients were 
followed-up to December 30, 2019, but there were 2 cases lost to follow-up. 
The median follow-up time was 34  months (range 8–142  months). After 
a month of treatment with SRS, the ORR and DCR were 71.4% and 
95.2%, respectively. During follow-up, 5 cases had radiographic progres-
sions, including 3 cases combined with increased AFP which were diagnosed 
with local recurrence and 2 cases diagnosed with GTS；The 3y-PFS and OS 
were 85.2% and 88.0%.no acute radiation response was found after treat-
ment with SRS, and only one patient had brain neurotoxicity. CONCLU-
SION: SRS for residual lesions of NGGCTs after RT is proved to be safe 
and feasible, with well tolerance, which is beneficial for the improvement of 
local control and the prolongation of survival.
GCT-64. TREATMENT RESULTS IN CHILDREN WITH LOCALIZED 
CNS NGGCT
Irina Vilesova1, Ekaterina Tarasova2, Andge Valiakhmetova3, 
Ekaterina Salnikova1, Alexey Pshonkin1, Galina Novichkova1, 
Alexander Karachunsky1, and Ludmila Papusha1; 1Dmitry Rogachev 
National Medical Research Center Of Pediatric Hematology, Oncology and 
Immunology, Moscow, Russian Federation, 2Russian Children’s Clinical 
Hospital, Moscow, Russian Federation, 3N. N. Burdenko National Medical 
Research Center of Neurosurgery, Moscow, Russian Federation
BACKGROUND/OBJECTIVES: Treatment of children with CNS 
NGGCT remains challenge: 5y OS is 60 – 80%; relapses are very aggres-
sive. DESIGN/METHODS: Between 2003 and 2019, 14 children (median 
age 10.5, range 4  – 16  years) with localized intracranial NGGCT were 
treated with RT after induction chemotherapy (focal – 4, WVI+boost – 6, 
WBI+boost – 3, CSI+boost – 1). Tumor markers were elevated in 13 pa-
tients: 6 – AFP, 5 – HCG, 2 – both. One patient with level of HCG 72049 
IU/l in serum and 121451 IU/l in CSF received 4 cycles of PEI + CSI 30 
Gy with boost 54Gy. RESULTS: At a median follow-up of 4,7 years (range 
1 – 16,25 years), 12 patients are alive. 5-year PFS and OS are 77,1% and 
85,7%, respectively. Two patients (both AFP and HCG) progressed during 
RT (1 – focal, 1 – WBI+boost), both died. Two patients with high level of 
HCG recurred after therapy (WVI+boost – 1, focal – 1), both are alive. The 
first of them at recurrence (mts of lateral ventricle) received 4 cycles of PEI 
and RT (WBI+boost). The second patient had level of HCG 620IU/l and ini-
tially received focal irradiation 54Gy. At recurrence with distant spinal mts 
he received HD-CHT with auto-SCT, surgical resection of residual tumor 
and CSI with boost. CONCLUSIONS: Good results of treatment of local-
ized CNS NGGCT with CSI, WBI or WVI in compare with focal RT show 
advantages of extended irradiation field. CSI should be considered for pa-
tients with extremely high levels of tumor markers and respectively poor 
prognostic histology.
GCT-65. INCIDENCE AND OUTCOME OF INTRACRANIAL 
MALIGNANT GERM CELL TUMOURS DIAGNOSED IN WESTERN 
DENMARK IN THE LAST DECADE
Yasmin Lassen-Ramshad1, Torben Stamm Mikkelsen2, Steen Rosthoej3, 
Louise Tram Henriksen2, Ruta Tuckuvienne3, Ines Ackerl Kristensen2, 
Gorm von Oettingen4, Soeren Cortnum4, Anne-Birgitte Als5, 
Akmal Safwat1,5, and Mads Agerbaek5; 1Danish Centre For Particle 
Therapy, Aarhus University Hospital, Aarhus, Denmark, 2Pediatric 
Department, Aarhus University Hospital, Aarhus, Denmark, 3Pediatric 
Department, Aalborg University Hospital, Aalborg, Denmark, 4Department 
of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark, 
5Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
INTRODUCTION: Intracranial malignant germ cell tumours (iGCT) 
are rare brain tumours mainly diagnosed in children and younger 
adults. MATERIAL AND METHODS: A retrospective analysis was per-
formed by chart review of patients treated for iGCT in the northern and 
central region of Denmark. Teratoma only patients were not included 
in the study.  RESULTS: 20 patients with iGCT were diagnosed from 
2008–2019 in Western Denmark. The cumulative incidence was 1.05 per 
100.000. The yearly incidence was 0.1 per 100.000. Mean age at diag-
nosis was 18  years (range 8–36  years), 17 were males and 3 were fe-
males. 13 patients presented with germinoma and 7 patients with non 
germinomateous germ cell tumours (NGGCT). Three patients had dissem-
inated disease, two with germinoma and one with NGGCT. All patients 
had received radiotherapy and 18 patients were treated with multidrug 
chemotherapy including platinum and etoposide before irradiation. Two 
patients experienced recurrent disease, both non disseminated at diag-
nosis, one patient with germinoma and one patient with NGGCT. Both re-
ceived salvage treatment including high dose chemotherapy with stem cell 
transplantation and reirradiation. Two NGGCT patients died, one patient 
after development of an anaplastic astrocytoma in the radiation field five 
years after radiotherapy and one patient after intracranial hemorraghe 
18 months after salvage treatment for recurrent disease. Overall survival 
was 90%, 100% for GCT and 71% for NGGCT. CONCLUSION: The 
outcome of patients with iGCT in Western Denmark was comparable to 
the literature. A nationwide study of epidemiology and outcome of iGCT 
in Denmark is planned.
GCT-66. FINAL REPORT OF THE PROSPECTIVE NEXT/CNS-GCT-4 
CONSORTIUM TRIAL (GEMPOX FOLLOWED BY MARROW-
ABLATIVE CHEMOTHERAPY) IN PATIENTS WITH REFRACTORY/
RECURRENT CNS GERM CELL TUMORS
Margaret Shatara1, Megan Blue1, Joseph R. Stanek1, 
Allison Y. Liu2, Diana S. Osorio1, Mohamed S. AbdelBaki1, 
Daniel Prevedello3, Vinay Puduvalli3, Pierre Giglio3, Sharon Gardner4, 
Jeffrey Allen4, Kenneth E. Wong5, Girish Dhall6,7, and Jonathan L Finlay1; 
1The Division of Hematology, Oncology, Blood and Marrow Transplant, 
Nationwide Children’s Hospital and The Ohio State University, Columbus, 
OH, USA, 2University of California-Davis Health, Sacramento, CA, USA, 
3The Ohio State University, Columbus, OH, USA, 4New York University 
School of Medicine, New York, New York, USA, 5Children’s Hospital 
of Los Angeles, Sacramento, CA, USA, 6The University of Alabama at 
Birmingham, Birmingham, AL, USA, 7Children’s Hospital of Alabama, 
Birmingham, AL, USA
BACKGROUND: We report the responses, toxicities and long-term 
outcomes of gemcitabine, paclitaxel and oxaliplatin (GemPOx) regimen 
administered, in responsive patients, prior to single cycle marrow-ablative 
chemotherapy (thiotepa, etoposide and carboplatin) with autologous hem-







ent_3/iii341/6018668 by Aalborg U
niversity Library user on 15 February 2021
